Roche's breast cancer franchise given boost by postive trial data

Two trials on Roche's blockbuster Herceptin wiped out a risk that they could have indicated a shorter period of treatment than the current recommendation of one year — a finding that could have cost up to US$1.5 billion in sales.

A third trial comparing Roche's experimental drug TDM-1 with a standard cocktail of drugs in patients with an aggressive form of advanced breast cancer showed the new drug helped patients live more than five months longer.

TDM-1, or trastuzumab emtansine, is an “armed antibody” drug being developed by Roche and Immunogen as a successor to Herceptin, which could be exposed to so-called “biosimilar” generic competition in Europe from around 2015.

SHARE CLOSE
Blogger		Google+
Live Journal		Plurk
Stumble Upon

Tweet

	PREVIOUS ARTICLE
	Asian markets mixed, Spain fears remove early shine

NEXT ARTICLE
Smartphones and tablets set to reshape the news industry: study

Write a Comment

Terms

Enter your comments - 3000 characters max

Type in image code

 Receive China Post promos
 Respond to this email

Submit